Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
To read the full story
Related Article
- Japan Doctors’ Lobby Braced for Tough Social Security Debate after Election
June 20, 2019
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
- Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More
June 12, 2019
REGULATORY
- Japan to Set Up Real-Time Tracking System for COVID-19 Vaccination: Kono
January 26, 2021
- MHLW Plans to Issue Vaccination Tickets to Elderly from Mid-March
January 26, 2021
- Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
- MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
- Japan Preps for COVID-19 Vaccine Rollout for HCPs by Late February: Minister
January 25, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…